Edition:
United Kingdom

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.49USD
6:04pm GMT
Change (% chg)

$-0.01 (-0.40%)
Prev Close
$2.50
Open
$2.49
Day's High
$2.49
Day's Low
$2.45
Volume
5,280
Avg. Vol
22,141
52-wk High
$7.15
52-wk Low
$2.00

Chart for

About

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as... (more)

Overall

Beta: 1.69
Market Cap(Mil.): $34.83
Shares Outstanding(Mil.): 11.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Pernix Announces Patent Litigation Settlement Agreement With Actavis

* PERNIX ANNOUNCES PATENT LITIGATION SETTLEMENT AGREEMENT WITH ACTAVIS CONCERNING ZOHYDRO® ER

29 Jan 2018

BRIEF-Pernix Therapeutics Will Reduce Workforce By 41 Employees

* PERNIX THERAPEUTICS HOLDINGS INC - WILL REDUCE WORKFORCE BY 41 EMPLOYEES; MAJORITY EXPECTED TO BE WITH CO'S SALES FORCE & COMMERCIAL INFRASTRUCTURE

05 Jan 2018

BRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mln

* Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​ Source text: (http://bit.ly/2jg0Ica) Further company coverage:

22 Nov 2017

BRIEF-Pernix Therapeutics posts Q3 revenue of $40.5 mln

* Pernix Therapeutics reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Pernix Therapeutics announces sale of non-core product

* Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​ Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Pernix Therapeutics says CFO and president Graham Miao resigns

* Pernix Therapeutics announces planned departure of chief financial officer

17 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $130.00 +0.09
Novartis AG (NOVN.S) CHF79.98 -0.22
Pfizer Inc. (PFE.N) $35.73 -0.03
Roche Holding Ltd. (ROG.S) CHF223.30 -0.20
Roche Holding Ltd. (RO.S) CHF226.40 -1.20
Merck & Co., Inc. (MRK.N) $54.65 +0.10

Earnings vs. Estimates